Home › Research › Brain tissue and pathology
Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, Reiman EM, Palmqvist S et al.. EMBO molecular medicine, 2021-05-05
Topic: Brain proteins, microglia and lab models
Plain-language summary
Alzheimer's disease is characterized by β-amyloid plaques and tau tangles. Plasma levels of phospho-tau217 (P-tau217) accurately differentiate Alzheimer's disease dementia from other dementias, but it is unclear to what degree this reflects β-amyloid plaque accumulation, tau tangle accumulation, or both. In a cohort with post-mortem neuropathological data (N = 88), both plaque and tangle density contributed independently to higher P-tau217, but P-tau217 was not elevated in patients with non-Alzheimer's disease tauopathies (N = 9).
What this study adds
Evidence grade: Moderate
The record lists 88 participants. In 88 people whose brains were examined after death, both amyloid plaques and tau tangles were independently linked to higher blood P-tau217, while levels were not raised in 9 people with other (non-Alzheimer's) tau diseases. In 426 living people scanned with PET (BioFINDER-2), P-tau217 tracked amyloid in early disease and both amyloid and, more strongly, tau in later disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mattsson-Carlgren, N., Janelidze, S., Bateman, R. J., Smith, R., Stomrud, E., Serrano, G. E., et al. (2021). Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO molecular medicine. https://doi.org/10.15252/emmm.202114022
Vancouver
Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO molecular medicine. 2021. doi:10.15252/emmm.202114022. PMID: 33949133.
BibTeX
@article{mattssoncarlgren2021-33949133,
author = {Mattsson-Carlgren, N. and Janelidze, S. and Bateman, R. J. and Smith, R. and Stomrud, E. and Serrano, G. E. and Reiman, E. M. and Palmqvist, S. and others},
title = {{Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau}},
journal = {EMBO molecular medicine},
year = {2021},
doi = {10.15252/emmm.202114022},
pmid = {33949133},
url = {https://doi.org/10.15252/emmm.202114022}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Plasma levels of phospho-tau217 (P-tau217) accurately differentiate Alzheimer's disease dementia from other dementias, but it is unclear to what degree this reflects β-amyloid plaque accumulation, tau tangle accumulation, or both.
- In a cohort with post-mortem neuropathological data (N = 88), both plaque and tangle density contributed independently to higher P-tau217, but P-tau217 was not elevated in patients with non-Alzheimer's disease tauopathies (N = 9).
- Several findings were replicated in a cohort with PET imaging ("BioFINDER-2", N = 426), where β-amyloid and tau PET were independently associated with P-tau217.
- P-tau217 concentrations correlated with β-amyloid PET (but not tau PET) in early disease stages and with both β-amyloid and (more strongly) tau PET in late disease stages.
Why it matters
In 88 people whose brains were examined after death, both amyloid plaques and tau tangles were independently linked to higher blood P-tau217, while levels were not raised in 9 people with other (non-Alzheimer's) tau diseases. In 426 living people scanned with PET (BioFINDER-2), P-tau217 tracked amyloid in early disease and both amyloid and, more strongly, tau in later disease. This is an association study supporting P-tau217 as a blood marker of Alzheimer's brain changes; it tests no treatment, and the non-Alzheimer's comparison is small.
Study details
- Participants88
- Evidence strengthModerate
How this study scored 61/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (EMBO molecular medicine) |
| Journal's citation record | 2 / 4 | EMBO Molecular Medicine: journal h-index 186 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2021 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 88 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 256 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 36.6 citations a year over 7 year(s) since 2021 |
| Impact for its field and year | 4 / 6 | Cited 17.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 52 other studies in this library |
| Still being cited | 3 / 4 | Cited 160 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33949133) |
| Free to read | 2 / 2 | Free to read |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.15252/emmm.202114022
- PubMed: 33949133
- Original source →
- Free full text: EMBO Molecular Medicine →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
52 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Brain tissue and pathology from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.